LAB

Company Overview — What Does STANDARD BIOTOOLS INC. Do?

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. STANDARD BIOTOOLS INC. (LAB) is classified as a small-cap stock in the Technology sector, specifically within the Measuring And Control Equipment industry. The company is led by CEO Michael Egholm and employs approximately 620 people, headquartered in South San Francisco, California. With a market capitalization of $358M, LAB is one of the notable companies in the Technology sector.

STANDARD BIOTOOLS INC. (LAB) Stock Rating — Reduce (April 2026)

As of April 2026, STANDARD BIOTOOLS INC. receives a Reduce rating with a composite score of 29.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.LAB ranks #3,890 out of 4,446 stocks in our coverage universe. Within the Technology sector, STANDARD BIOTOOLS INC. ranks #476 of 584 stocks, placing it in the lower half of its Technology peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LAB Stock Price and 52-Week Range

STANDARD BIOTOOLS INC. (LAB) currently trades at $0.89. The stock lost $0.03 (2.8%) in the most recent trading session. The 52-week high for LAB is $1.72, which means the stock is currently trading -48.5% from its annual peak. The 52-week low is $0.92, putting the stock -3.8% above its annual trough. Recent trading volume was 2.7M shares, reflecting moderate market activity.

Is LAB Overvalued or Undervalued? — Valuation Analysis

STANDARD BIOTOOLS INC. (LAB) carries a value factor score of 17/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.85x, versus the sector average of 3.16x. The price-to-sales ratio is 2.84x, compared to 1.06x for the average Technology stock.

At current multiples, STANDARD BIOTOOLS INC. trades at a premium to most Technology peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

STANDARD BIOTOOLS INC. Profitability — ROE, Margins, and Quality Score

STANDARD BIOTOOLS INC. (LAB) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -28.5%, compared to the Technology sector average of -1.4%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -21.3% versus the sector average of -1.0%.

On a margin basis, STANDARD BIOTOOLS INC. reports gross margins of 49.4%, compared to 50.9% for the sector. The operating margin is -109.5% (sector: -0.5%). Net profit margin stands at -113.7%, versus -1.5% for the average Technology stock. Revenue growth is running at -47.4% on a trailing basis, compared to 14.2% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

LAB Debt, Balance Sheet, and Financial Health

STANDARD BIOTOOLS INC. has a debt-to-equity ratio of 34.0%, compared to the Technology sector average of 43.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.19x, indicating strong short-term liquidity. Total debt on the balance sheet is $299,000. Cash and equivalents stand at $129M.

LAB has a beta of 1.40, meaning it is more volatile than the broader market — a $10,000 investment in LAB would be expected to move 39.7% more than the S&P 500 on any given day. The stability factor score for STANDARD BIOTOOLS INC. is 37/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

STANDARD BIOTOOLS INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, STANDARD BIOTOOLS INC. reported revenue of $127M and earnings per share (EPS) of $-0.20. Net income for the quarter was $-121M. Gross margin was 49.4%. Operating income came in at $-123M.

In FY 2025, STANDARD BIOTOOLS INC. reported revenue of $85M and earnings per share (EPS) of $-0.20. Net income for the quarter was $-75M. Gross margin was 49.9%. Revenue grew -51.1% year-over-year compared to FY 2024. Operating income came in at $-110M.

In Q3 2025, STANDARD BIOTOOLS INC. reported revenue of $20M and earnings per share (EPS) of $-0.09. Net income for the quarter was $-35M. Gross margin was 48.5%. Revenue grew -56.5% year-over-year compared to Q3 2024. Operating income came in at $-33M.

In Q2 2025, STANDARD BIOTOOLS INC. reported revenue of $22M and earnings per share (EPS) of $-0.09. Net income for the quarter was $-33M. Gross margin was 48.8%. Revenue grew -41.5% year-over-year compared to Q2 2024. Operating income came in at $-26M.

Over the past 8 quarters, STANDARD BIOTOOLS INC. has demonstrated a growth trajectory, with revenue expanding from $37M to $127M. Investors analyzing LAB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LAB Dividend Yield and Income Analysis

STANDARD BIOTOOLS INC. (LAB) does not currently pay a dividend. This is common among smaller companies in the Measuring And Control Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Technology dividend stocks may want to explore other Technology stocks or use the stock screener to filter by dividend yield.

LAB Momentum and Technical Analysis Profile

STANDARD BIOTOOLS INC. (LAB) has a momentum factor score of 27/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 50/100 reflects moderate short selling activity.

LAB vs Competitors — Technology Sector Ranking and Peer Comparison

Within the Technology sector, STANDARD BIOTOOLS INC. (LAB) ranks #476 out of 584 stocks based on the Blank Capital composite score. This places LAB in the lower half of all Technology stocks in our coverage universe. Key competitors and sector peers include IHS Holding Ltd (IHS) with a score of 55.0/100, VERISIGN INC/CA (VRSN) with a score of 56.0/100, ESCO TECHNOLOGIES INC (ESE) with a score of 51.7/100, CareCloud, Inc. (CCLD) with a score of 46.9/100, and MMTec, Inc. (MTC) with a score of 47.4/100.

Comparing LAB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LAB vs S&P 500 (SPY) comparison to assess how STANDARD BIOTOOLS INC. stacks up against the broader market across all factor dimensions.

LAB Next Earnings Date

No upcoming earnings date has been announced for STANDARD BIOTOOLS INC. (LAB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LAB? — Investment Thesis Summary

The quantitative profile for STANDARD BIOTOOLS INC. suggests caution. The quality score of 26/100 flags below-average profitability. The value score of 17/100 indicates premium valuation. Momentum is weak at 27/100, a headwind for near-term performance. High volatility (stability score 37/100) increases portfolio risk.

In summary, STANDARD BIOTOOLS INC. (LAB) earns a Reduce rating with a composite score of 29.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LAB stock.

Related Resources for LAB Investors

Explore more research and tools: LAB vs S&P 500 comparison, top Technology stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LAB head-to-head with peers: LAB vs IHS, LAB vs VRSN, LAB vs ESE.